Biotech News

Voyager to Present at Upcoming Investor Conferences

Voyager Therapeutics (VYGR)Voyager TherapeuticsConference / presentation

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.

2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.

Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.

Baird’s 2026 Global Healthcare Conference: Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.

H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.

A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com . A replay of the webcast will be archived on the company’s website for at least 30 days.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts Company and Investors: Trista Morrison, NACD.DC, tmorrison@vygr.com Media: Lisa Guiterman, [email protected]

Related news

Voyager Therapeutics

Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs. TRACER Capsid Platform The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous...

Recent company news

Stock data

Close
3.04 USD
Market cap
216.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States